NRx Defense Systems awarded DARPA prime contract worth up to $11.2M for SPARC-TMS trial

NRX Pharmaceuticals, Inc.

NRx Defense Systems, an NRx Pharmaceuticals subsidiary, won a DARPA prime contract with aggregate value about $11.2 million and $6.7 million initially obligated.
The contract has an 18-month performance period and milestone payments; DARPA receives a nonexclusive license while NRx Defense retains ownership of inventions.
SPARC-TMS will evaluate single-day robotic neuronavigated TMS plus NRX-101 for treatment-resistant depression; FDA-approved trial NCT07227103 is expected to begin enrolling.
Partners include HOPE Therapeutics, Harvard Medical School's McLean Hospital, Arizona State University, Zeta Surgical Systems, and Neurocare of America.
If replicated, results could support an FDA registration study; DARPA cited 8.9 million American adults and a $44 billion burden of treatment-resistant depression.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.